Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

Therapeutic Effects of Human Mesenchymal Stem Cell-Derived Microvesicles in Severe Pneumonia in Mice.

Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Rosenzwajg M, Matthay MA, Lee JW.

Am J Respir Crit Care Med. 2015 Jun 11. [Epub ahead of print]

PMID:
26067592
2.

Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.

Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg M, Klatzmann D.

Front Immunol. 2015 Apr 15;6:171. doi: 10.3389/fimmu.2015.00171. eCollection 2015.

3.

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D.

J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.

PMID:
25634360
4.

Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.

Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, Terrier B, Geri G, Rosenzwajg M, Klatzmann D, Fourret P, Cluzel P, Chiche L, Gaudric J, Koskas F, Cacoub P.

Arthritis Rheumatol. 2015 May;67(5):1353-60. doi: 10.1002/art.39037.

PMID:
25604824
5.

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes.

Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, Malek TR.

Diabetes. 2015 Jun;64(6):2172-83. doi: 10.2337/db14-1322. Epub 2015 Jan 9.

PMID:
25576057
6.

Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.

Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D.

Curr Diab Rep. 2014 Dec;14(12):553. doi: 10.1007/s11892-014-0553-6. Review.

PMID:
25344788
7.

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone JA.

Blood. 2014 Dec 4;124(24):3572-6. doi: 10.1182/blood-2014-07-587493. Epub 2014 Oct 16.

8.

Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study.

Maury S, Rosenzwajg M, Redjoul R, Marcais A, Xhaard A, Cherai M, Cabanne L, Churlaud G, Suarez F, Socié G, Gregoire L, Debbache K, Bernard C, Beaumont JL, Azar N, Boyer O, Roudot-Thoraval F, Cohen JL, Cordonnier C, Lemoine FM, Klatzmann D.

Leukemia. 2014 Dec;28(12):2406-10. doi: 10.1038/leu.2014.237. Epub 2014 Aug 8. No abstract available.

PMID:
25102947
9.

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8.

PMID:
24622415
10.

Th1 response and systemic treg deficiency in inclusion body myositis.

Allenbach Y, Chaara W, Rosenzwajg M, Six A, Prevel N, Mingozzi F, Wanschitz J, Musset L, Charuel JL, Eymard B, Salomon B, Duyckaerts C, Maisonobe T, Dubourg O, Herson S, Klatzmann D, Benveniste O.

PLoS One. 2014 Mar 4;9(3):e88788. doi: 10.1371/journal.pone.0088788. eCollection 2014.

11.

CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis.

Terrier B, Nagata S, Ise T, Rosenzwajg M, Pastan I, Klatzmann D, Saadoun D, Cacoub P.

Arthritis Rheumatol. 2014 Feb;66(2):433-43. doi: 10.1002/art.38222.

PMID:
24504816
12.

Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection.

Terrier B, Chaara W, Dufat L, Geri G, Rosenzwajg M, Musset L, Sène D, Saadoun D, Six A, Klatzmann D, Cacoub P.

Autoimmun Rev. 2014 Mar;13(3):319-26. doi: 10.1016/j.autrev.2013.11.001. Epub 2013 Nov 9. Review.

PMID:
24220267
13.

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L.

Oncoimmunology. 2013 Feb 1;2(2):e23080.

14.

Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation.

Saadoun D, Terrier B, Bannock J, Vazquez T, Massad C, Kang I, Joly F, Rosenzwajg M, Sene D, Benech P, Musset L, Klatzmann D, Meffre E, Cacoub P.

Arthritis Rheum. 2013 Apr;65(4):1085-96. doi: 10.1002/art.37828.

15.

Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation.

Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, Mariampillai K, Rosenzwajg M, Carpentier W, Musset L, Piette JC, Six A, Klatzmann D, Saadoun D, Patrice C, Costedoat-Chalumeau N.

Arthritis Res Ther. 2012 Oct 17;14(5):R221. doi: 10.1186/ar4060.

16.

Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus.

Terrier B, Costedoat-Chalumeau N, Garrido M, Geri G, Rosenzwajg M, Musset L, Klatzmann D, Saadoun D, Cacoub P.

J Rheumatol. 2012 Sep;39(9):1819-28. doi: 10.3899/jrheum.120468. Epub 2012 Aug 1.

PMID:
22859347
17.

Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy.

Touil S, Rosenzwajg M, Landau DA, Le Corvoisier P, Frédéric C, Klatzmann D, Maury S, Cohen JL.

Haematologica. 2012 Nov;97(11):1678-85. doi: 10.3324/haematol.2011.056374. Epub 2012 May 11.

18.

Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis.

Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, Fouret P, Musset L, Benveniste O, Six A, Klatzmann D, Saadoun D, Cacoub P.

Arthritis Rheum. 2012 Jun;64(6):2001-11. doi: 10.1002/art.34327. Epub 2011 Dec 6.

19.

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D.

N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

20.

Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity.

Terrier B, Joly F, Vazquez T, Benech P, Rosenzwajg M, Carpentier W, Garrido M, Ghillani-Dalbin P, Klatzmann D, Cacoub P, Saadoun D.

J Immunol. 2011 Dec 15;187(12):6550-63. doi: 10.4049/jimmunol.1102022. Epub 2011 Nov 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk